Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective October 16, 2026, it granted stock options to purchase an aggregate of 570,000 shares of common stock to three newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
Covered in this story
Call it yourself
No calls on $GERN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Geron Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.